Filtered By:
Education: Study
Nutrition: Herbs
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 496 results found since Jan 2013.
Molecules, Vol. 28, Pages 2598: Gastrodin and Gastrodigenin Improve Energy Metabolism Disorders and Mitochondrial Dysfunction to Antagonize Vascular Dementia
This study explored the effects of Gas and HBA on cognitive dysfunction in VD and their possible molecular mechanisms. The VD model was established by bilateral common carotid artery ligation (2-vessel occlusion, 2-VO) combined with an intraperitoneal injection of sodium nitroprusside solution. One week after modeling, Gas (25 and 50 mg/kg, i.g.) and HBA (25 and 50 mg/kg, i.g.) were administered orally for four weeks, and the efficacy was evaluated. A Morris water maze test and passive avoidance test were used to observe their cognitive function, and H&E staining and Nissl staining were used to observe the neur...
Source: Molecules - March 13, 2023 Category: Chemistry Authors: Sha Wu Rong Huang Ruiqin Zhang Chuang Xiao Lueli Wang Min Luo Na Song Jie Zhang Fang Yang Xuan Liu Weimin Yang Tags: Article Source Type: research
Investigating the in vivo effect of Tribulus terrestris extract in MCAO rats by using LC-MS-based metabolomics combined with the molecular docking
This study aimed to investigate the protective effect of TT extract, named TT15, on middle cerebral artery occlusion (MCAO) rats by metabolomics and molecular docking, and find the targets of action and the material basis of TT15 against IS. The results of the infarct volume and neurological defect scores confirmed the efficacy of TT15. The serum metabolomics analysis using LC-MS revealed that Model group animals experienced a variety of metabolic disturbances when compared to the Sham group. TT15 can restore the MCAO-induced serum metabolite changes by modulating multiple metabolic pathways. Six enzymes were highlighted b...
Source: Biomedical Chromatography : BMC - March 8, 2023 Category: Biomedical Science Authors: Xingxing Li Wenjun Guo Liang Zhao Dandan Xu Xiaohang Xu Yuqing Han Chengyan Wang Yingzi Jiang Yang Wang Yajuan Xu Source Type: research
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Bioactive Compounds (BACs): A Novel Approach to Treat and Prevent Cardiovascular Diseases
Curr Probl Cardiol. 2023 Feb 23:101664. doi: 10.1016/j.cpcardiol.2023.101664. Online ahead of print.ABSTRACTCardiovascular diseases (CVDs) are one of the leading disorders of serious death and cause huge economic loss to patients and society. It is estimated that about 18 million people have a high death ratio due to the incidence of CVDs such as (stroke, coronary heart disease, and non-ischemic heart failure). Bioactive compounds (BACs) are healthy nutritional ingredients providing beneficial effects and nutritional value to the human body. Epidemiological studies strongly shed light on several bioactive compounds that ar...
Source: Atherosclerosis - February 25, 2023 Category: Cardiology Authors: Syed Riaz Ud Din Sumbul Saeed Shahid Ullah Khan Mintao Zhong Source Type: research
Alternative medicine therapies in neurological disorders: Prevalence, reasons and associated factors. A systematic review
CONCLUSIONS: The prevalence of CAM use in neurological diseases is highly variable (16%-100%); the most used type of CAM was biological therapies and the associated factors were female sex, age between 40 and 50 years old and high socioeconomic level.PMID:36805318 | DOI:10.1016/j.ctim.2023.102932
Source: Complementary Therapies in Medicine - February 22, 2023 Category: Complementary Medicine Authors: Mar ía Soto-Lara Melissa Silva-Loredo Jos é Rodrigo Monroy-Córdoba Paola Flores-Ordo ñez Nelly G Cervera-Delgadillo Paul Carrillo-Mora Source Type: research
Astragaloside IV mitigates cerebral ischaemia-reperfusion injury via inhibition of P62/Keap1/Nrf2 pathway-mediated ferroptosis
This study examined the mechanisms underlying the anti-CIRI action of AST IV using a combination of in vitro and in vivo approaches. We established an erastin-induced ferroptosis model, oxygen and glucose deprivation/reoxygenation (OGD/R)-induced model in SH-SY5Y cells, and middle cerebral artery occlusion-reperfusion (MCAO/R) model using Sprague-Dawley rats. The extent of cell damage and brain damage in rats, ferroptosis indicator changes, and expression of P62, Keap1, and Nrf2 were investigated. AST IV inhibited erastin-induced ferroptosis, attenuated OGD/R-induced cell damage, and ameliorated sensorimotor dysfunction an...
Source: European Journal of Pharmacology - February 9, 2023 Category: Drugs & Pharmacology Authors: Lele Wang Canwen Liu Linlin Wang Biao Tang Source Type: research
Network pharmacology and experimental study of phenolic acids in salvia miltiorrhiza bung in preventing ischemic stroke
At present, the preventive effect of ischemic stroke is not ideal, and the preventive drugs are limited. Danshen, the dried root of Salvia miltiorrhiza Bge, is a common medicinal herb in Traditional Chinese Medicine, which has been used for the treatment of cardiovascular diseases for many years. Phenolic Acids extracted from danshen, which showed multiple biological activities, have been developed as an injection for the treatment of ischemic stroke. However, its preventive effect on ischemic stroke has not been fully reported. The current study aimed to identify the potential active phenolic acids for the prevention of i...
Source: Frontiers in Pharmacology - January 27, 2023 Category: Drugs & Pharmacology Source Type: research
The quality of reporting of randomized controlled trials of HuatuoZaizao pill for stroke
Conclusion: The overall report quality of RCT related to HZP is low. HZP still needs to report higher quality RCTs to prove its effectiveness and safety.
Source: Frontiers in Pharmacology - January 10, 2023 Category: Drugs & Pharmacology Source Type: research
Efficacy of Chinese herbal medicine on poststroke depression in animal models: A systematic review and meta-analysis
ConclusionOur results suggest that CHM could significantly improve depression-like behavior and neurological function in animals with PSD. The current results should be interpreted with caution because only animal studies were included.
Source: Frontiers in Neurology - January 9, 2023 Category: Neurology Source Type: research
Efficacy and safety of naotaifang capsules for hypertensive cerebral small vessel disease: Study protocol for a multicenter, randomized, double-blind, placebo-controlled clinical trial
Conclusion: The protocol will comfirm whether naotaifang capsules reduce Fazekas scores, dilated Virchow-robin spaces grades, and the number of lacunar infarctions and cerebral microbleeds, clinical blood pressure, increase mini-mental state examination scores, traditional Chinese medicine syndrome scores of Qi deficiency and blood stasis (QDBS), and improve the quality of life of subjects. The consolidated evidence from this study will shed light on the benefits of Chinese herbs for hypertensive cerebral small vessel disease, such as nourishing qi, promoting blood circulation and removing blood stasis, and dredging collat...
Source: Frontiers in Pharmacology - January 6, 2023 Category: Drugs & Pharmacology Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
